David Steffin is an Oncology physician affiliated with Houston Methodist. OpenAlex indexes 42 publications with 422 citations (h-index 9); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6701 Fannin St Ste 1510
Clinical Care Center, Texas Children'S Hospital
Houston, TX 77030
Telephone
832-822-4242Provider last certified this registry record 29 Mar 2023.
Clinical trials
- GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT)
Sponsor: Baylor College of Medicine
- Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Sponsor: Baylor College of Medicine
- Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Sponsor: Baylor College of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- National Marrow Donor ProgramProgram year20241 payment
- SOBI, INCProgram year20241 payment
- National Marrow Donor ProgramProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors
Pediatric Blood & Cancer
2025 - 553 A phase I clinical trial of allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B cell malignancies: an interim analysis
Regular and Young Investigator Award Abstracts
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Bita Esmaeli, MD
Houston Methodist
Sherif Nagueh, MD
Houston Methodist
Neal Kleiman, MD
Houston Methodist
Miguel Quinones, MD
Houston Methodist
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”